|
Report No. : |
313400 |
|
Report Date : |
24.03.2015 |
IDENTIFICATION DETAILS
|
Name : |
MARPEL PHARMA S. A |
|
|
|
|
Registered Office : |
Bodega #7 del cruce de Multiplaza Escazù 800 metros Noroeste San José |
|
|
|
|
Country : |
Costa
Rica |
|
|
|
|
Date of Incorporation : |
2003 |
|
|
|
|
Legal Form : |
Sociedad Anonima |
|
|
|
|
Line of Business : |
Manufacturer and Wholesaler of Pharmaceutical Products |
|
|
|
|
No. of Employees : |
20 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
Slow but correct |
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – December 31, 2014
|
Country Name |
Previous Rating (30.09.2014) |
Current Rating (31.12.2014) |
|
Costa Rica |
A1 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
COSTA RICA - ECONOMIC OVERVIEW
Prior to the global economic crisis,
Costa Rica enjoyed stable economic growth. The economy contracted 1.3% in 2009
but resumed growth at about 4.5% per year in 2010-12. While the traditional
agricultural exports of bananas, coffee, sugar, and beef are still the backbone
of commodity export trade, a variety of industrial and specialized agricultural
products have broadened export trade in recent years. High value-added goods
and services, including microchips, have further bolstered exports. Tourism
continues to bring in foreign exchange, as Costa Rica's impressive biodiversity
makes it a key destination for ecotourism. Foreign investors remain attracted
by the country's political stability and relatively high education levels, as
well as the incentives offered in the free-trade zones; and Costa Rica has
attracted one of the highest levels of foreign direct investment per capita in
Latin America. However, many business impediments remain, such as high levels
of bureaucracy, legal uncertainty due to overlapping and at times conflicting responsibilities
between agencies, difficulty of enforcing contracts, and weak investor
protection. Poverty has remained around 20-25% for nearly 20 years, and the
strong social safety net that had been put into place by the government has
eroded due to increased financial constraints on government expenditures.
Unlike the rest of Central America, Costa Rica is not highly dependent on
remittances as they only represent about 2% of GDP. Immigration from Nicaragua
has increasingly become a concern for the government. The estimated
300,000-500,000 Nicaraguans in Costa Rica legally and illegally are an
important source of mostly unskilled labor but also place heavy demands on the
social welfare system. The US-Central American-Dominican Republic Free Trade
Agreement (CAFTA-DR) entered into force on 1 January 2009 after significant
delays within the Costa Rican legislature. CAFTA-DR has increased foreign
direct investment in key sectors of the economy, including the insurance and
telecommunications sectors recently opened to private investors. President
CHINCHILLA was not able to gain legislative approval for fiscal reform, her top
priority, though she continued to pursue fiscal reform in 2012. President
CHINCHILLA and the PLN were successful in passing a tax on corporations to fund
an increase for security services.
|
Source
: CIA |
STATUTORY
INFORMATION
|
|
|
Legal Name: |
MARPEL PHARMA S. A |
|
Trade Name: |
MARPEL PHARMA |
|
Cedula Juridica: |
3-101-388589 |
|
Date Created: |
2003 |
|
Date Incorporated: |
2003 |
|
Legal Address: |
Bodega #7 del cruce de Multiplaza Escazù 800 metros Noroeste San José
Costa Rica |
|
Operative Address: |
Calle Mata Palo, Multibobegas # 7 frente al Blue Valley Guachipelin de
Escazu, San Jose, Costa Rica. Costa Rica |
|
Telephone: |
(506) 2215 4215 |
|
Fax: |
(506) 2215-4214 |
|
Legal Form: |
Sociedad Anonima |
|
Email: |
Info@marpelpharma.com |
|
Registered in: |
Costa Rica |
|
Website: |
www.marpelpharma.com |
|
Contact: |
Randal Mauricio Palma Peace |
|
Staff: |
20 |
|
Activity: |
Drugs and Druggists' Sundries Merchant Wholesalers |
|
BANKS |
Banco Central de Costa Rica |
|
|
|
|
|
The company does not make its banking data public |
|
|
|
|
HISTORY |
Marpel Pharma began operations in Costa Rica in 2003 with the aim of offering
market Drugs and biomedical products. |
|
|
|
|
PRINCIPAL ACTIVITY |
This is a manufacturer and wholesaler of Pharmaceutical Products |
|
Products/Services description: |
Medications |
|
Brands: |
Marpel Pharma |
|
Sales are: |
Wholesale |
|
Clients: |
Government institutions, hospitals, clinics and physicians. |
|
Suppliers: |
Alpa Laboratories Limited |
|
Operations area: |
National and International |
|
The company imports from |
Spain |
|
The company exports to |
Latin America |
|
The subject employs |
20 employees |
|
Payments: |
Slow but correct |
|
|
|
LOCATION
|
|
|
Headquarters : |
Calle Mata Palo, Multibobegas # 7 frente al Blue Valley Guachipelin de
Escazu, San Jose, Costa Rica. Costa Rica |
|
Branches: |
The company does not have branches |
|
Industry: |
Companies in this industry distribute professional medical equipment,
instruments, and supplies to physicians, hospitals, and extended care
facilities. Demand depends on the number of people receiving medical treatment and
advances in medical technology. The profitability of individual companies
depends on merchandising and efficient delivery systems. Large companies have
economies of scale in purchasing, as well as highly developed infrastructure
that allow for efficient distribution. Small companies can compete
effectively by specializing in a product line or by serving a local market. Major products include medical and surgical instruments and equipment
(about 55 percent of revenue); supplies (about 25 percent); and orthopedic
and prosthetic appliances (10 percent). Other products include dental and
veterinary equipment and supplies. Some companies carry more than 250,000
stock-keeping units (SKUs), while others specialize in niche markets and may
carry only a few different items to serve a local market’s specific needs. |
|
|
|
GROUP
STRUCTURE AND SUBSIDIARY COMPANIES
|
|
|
Listed at the stock exchange: |
NO |
|
Capital: |
N/A |
|
Shareholders %: |
This is a private company, major holder is Philip Unger. |
|
Management: |
Maribel Flores Mora, Secretary |
|
Related Companies: |
Marpel Pharma México, S.A. de C.V |
|
|
The company has branches in:
Costa Rica |
FINANCIAL
INFORMATION
|
|
|
|
This is a private company which does not make its financial statements
public. The following data has been
provided by outside sources. |
|
|
|
|
2013 USD |
|
|
Revenue |
900 000 |
|
Cash Flow |
Normal |
|
|
|
|
|
The company's group revenue is estimated between USD 2.5 and 5
million. |
LEGAL
FILINGS
|
|
|
|
There are no legal connected to the subject |
|
|
|
|
SUMMARY |
Marpel Pharma began operations in Costa Rica in 2003. It is dedicated to
the Wholesale of Pharmaceutical Products. |
|
|
The company has a small sized strcuture with 20 employees, however, it
has presence in various countries from Latin America, such as Mexico, El
Slvador, Guatemala and Argentina. |
|
|
There are no negative. |
|
|
|
RISK
INFORMATION
|
|
|
DEBTS |
Controlled |
|
PAYMENTS |
Slow but correct |
|
CASH FLOW |
Normal |
|
STATUS |
Active |
|
|
|
|
ENTERVIEW |
|
|
NAME |
NA |
|
POSITION |
Administrative |
|
COMMENTS |
The person contacted confirmed clients, address, products and
managers. |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.62.29 |
|
|
1 |
Rs.93.02 |
|
Euro |
1 |
Rs.67.36 |
INFORMATION DETAILS
|
Analysis Done by
: |
DIV |
|
|
|
|
Report Prepared
by : |
TPT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
|
41-55 |
Ba |
Overall operation
is considered normal. Capable to meet normal commitments. |
Satisfactory |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
|
-- |
NB |
New Business |
-- |
|
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major sections
of this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.